S&P 500   4,226.05 (-1.45%)
DOW   32,990.44 (-1.32%)
QQQ   354.94 (-1.75%)
AAPL   171.80 (-1.12%)
MSFT   312.49 (-2.89%)
META   300.05 (-2.21%)
GOOGL   132.65 (-1.13%)
AMZN   124.89 (-3.53%)
TSLA   247.67 (-1.56%)
NVDA   436.58 (-2.51%)
NIO   8.68 (-1.25%)
BABA   84.50 (-2.35%)
AMD   100.04 (-3.13%)
T   14.70 (+0.20%)
F   12.04 (-2.19%)
MU   68.05 (+0.13%)
CGC   0.69 (-5.90%)
GE   107.68 (-1.02%)
DIS   79.76 (-2.34%)
AMC   8.06 (-1.10%)
PFE   33.99 (+0.15%)
PYPL   57.52 (-1.78%)
NFLX   375.76 (-1.20%)
S&P 500   4,226.05 (-1.45%)
DOW   32,990.44 (-1.32%)
QQQ   354.94 (-1.75%)
AAPL   171.80 (-1.12%)
MSFT   312.49 (-2.89%)
META   300.05 (-2.21%)
GOOGL   132.65 (-1.13%)
AMZN   124.89 (-3.53%)
TSLA   247.67 (-1.56%)
NVDA   436.58 (-2.51%)
NIO   8.68 (-1.25%)
BABA   84.50 (-2.35%)
AMD   100.04 (-3.13%)
T   14.70 (+0.20%)
F   12.04 (-2.19%)
MU   68.05 (+0.13%)
CGC   0.69 (-5.90%)
GE   107.68 (-1.02%)
DIS   79.76 (-2.34%)
AMC   8.06 (-1.10%)
PFE   33.99 (+0.15%)
PYPL   57.52 (-1.78%)
NFLX   375.76 (-1.20%)
S&P 500   4,226.05 (-1.45%)
DOW   32,990.44 (-1.32%)
QQQ   354.94 (-1.75%)
AAPL   171.80 (-1.12%)
MSFT   312.49 (-2.89%)
META   300.05 (-2.21%)
GOOGL   132.65 (-1.13%)
AMZN   124.89 (-3.53%)
TSLA   247.67 (-1.56%)
NVDA   436.58 (-2.51%)
NIO   8.68 (-1.25%)
BABA   84.50 (-2.35%)
AMD   100.04 (-3.13%)
T   14.70 (+0.20%)
F   12.04 (-2.19%)
MU   68.05 (+0.13%)
CGC   0.69 (-5.90%)
GE   107.68 (-1.02%)
DIS   79.76 (-2.34%)
AMC   8.06 (-1.10%)
PFE   33.99 (+0.15%)
PYPL   57.52 (-1.78%)
NFLX   375.76 (-1.20%)
S&P 500   4,226.05 (-1.45%)
DOW   32,990.44 (-1.32%)
QQQ   354.94 (-1.75%)
AAPL   171.80 (-1.12%)
MSFT   312.49 (-2.89%)
META   300.05 (-2.21%)
GOOGL   132.65 (-1.13%)
AMZN   124.89 (-3.53%)
TSLA   247.67 (-1.56%)
NVDA   436.58 (-2.51%)
NIO   8.68 (-1.25%)
BABA   84.50 (-2.35%)
AMD   100.04 (-3.13%)
T   14.70 (+0.20%)
F   12.04 (-2.19%)
MU   68.05 (+0.13%)
CGC   0.69 (-5.90%)
GE   107.68 (-1.02%)
DIS   79.76 (-2.34%)
AMC   8.06 (-1.10%)
PFE   33.99 (+0.15%)
PYPL   57.52 (-1.78%)
NFLX   375.76 (-1.20%)
NASDAQ:KPRX

Kiora Pharmaceuticals (KPRX) Stock Forecast, Price & News

$0.57
-0.02 (-3.39%)
(As of 01:12 PM ET)
Compare
Today's Range
$0.57
$0.60
50-Day Range
$0.48
$0.63
52-Week Range
$0.46
$10.39
Volume
174,148 shs
Average Volume
678,911 shs
Market Capitalization
$4.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.00

Kiora Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7,763.2% Upside
$46.00 Price Target
Short Interest
Healthy
3.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Kiora Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.74) to ($0.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars


KPRX stock logo

About Kiora Pharmaceuticals (NASDAQ:KPRX) Stock

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

KPRX Price History

KPRX Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Why Is Kiora Pharmaceuticals (KPRX) Stock Up 11% Today?
8-K: KIORA PHARMACEUTICALS INC
Kiora Heralds Public Offering
See More Headlines
Receive KPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KPRX Company Calendar

Last Earnings
8/08/2023
Today
10/03/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPRX
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.00
High Stock Price Forecast
$119.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+7,930.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-13,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$9.99 per share

Miscellaneous

Free Float
7,179,000
Market Cap
$4.15 million
Optionable
Not Optionable
Beta
-0.24
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Brian M. Strem Ph.D. (Age 43)
    Pres, CEO & Director
    Comp: $464.93k
  • Ms. Melissa Tosca CPA (Age 43)
    Exec. VP of Fin.
    Comp: $282.28k
  • Dr. Eric J. Daniels M.B.A. (Age 50)
    M.D., Chief Devel. Officer
    Comp: $371.47k
  • Dr. Stefan Sperl Ph.D.
    Exec. VP of CMC & Operations













KPRX Stock - Frequently Asked Questions

Should I buy or sell Kiora Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPRX shares.
View KPRX analyst ratings
or view top-rated stocks.

What is Kiora Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month price objectives for Kiora Pharmaceuticals' shares. Their KPRX share price forecasts range from $7.00 to $119.00. On average, they anticipate the company's share price to reach $46.00 in the next twelve months. This suggests a possible upside of 7,930.7% from the stock's current price.
View analysts price targets for KPRX
or view top-rated stocks among Wall Street analysts.

How have KPRX shares performed in 2023?

Kiora Pharmaceuticals' stock was trading at $3.43 at the beginning of 2023. Since then, KPRX shares have decreased by 83.3% and is now trading at $0.5728.
View the best growth stocks for 2023 here
.

Are investors shorting Kiora Pharmaceuticals?

Kiora Pharmaceuticals saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 252,600 shares, a decrease of 30.6% from the August 31st total of 364,200 shares. Based on an average daily volume of 325,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 3.8% of the company's stock are sold short.
View Kiora Pharmaceuticals' Short Interest
.

When is Kiora Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our KPRX earnings forecast
.

How were Kiora Pharmaceuticals' earnings last quarter?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) released its earnings results on Tuesday, August, 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.28.

When did Kiora Pharmaceuticals' stock split?

Kiora Pharmaceuticals's stock reverse split on the morning of Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Kiora Pharmaceuticals' stock symbol?

Kiora Pharmaceuticals trades on the NASDAQ under the ticker symbol "KPRX."

How do I buy shares of Kiora Pharmaceuticals?

Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiora Pharmaceuticals' stock price today?

One share of KPRX stock can currently be purchased for approximately $0.57.

How much money does Kiora Pharmaceuticals make?

Kiora Pharmaceuticals (NASDAQ:KPRX) has a market capitalization of $4.15 million and generates $10,000.00 in revenue each year.

How can I contact Kiora Pharmaceuticals?

Kiora Pharmaceuticals' mailing address is 271 Waverley Oaks Rd Ste 108, Waltham, Massachusetts 02452-8475. The official website for the company is eyegatepharma.com. The company can be reached via phone at (781) 788-9043 or via email at cdavis@lifesciadvisors.com.

This page (NASDAQ:KPRX) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -